{"ticker": {"uuid": "b180c0a5-e08a-427c-a9b2-b0c81bc198e8", "symbol": "CMC", "name": "Commercial Metals Company", "exchange": "NYSE", "country": "US", "sector": "Industrials", "industry": "Metal Fabrication"}, "articles": [{"title": "Inovio (INO) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Director of Communications - Jennie WillsonPresident and Chief Executive Officer - Dr. Jacqueline E. SheaChief Medical Officer - Dr. Michael SumnerChief Commercial Officer - Steven EggeChief Financial Officer - Peter D. Kies TAKEAWAYS INO-3107 PDUFA Date -- Oct. 30, 2026, for the Inovio Pharmaceuticals, Inc.(NASDAQ:INO) Biologics License Application (BLA), representing the target action date for regulatory review.Cash and Cash Equivalents -- $36.7 million as of June 30, 2026, a decrease from $58.5 mi", "url": "https://www.nasdaq.com/articles/inovio-ino-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-13T00:58:58+00:00", "published_display": "13 Aug 2026 00:58", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.427, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Financial Results"]}, {"title": "PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program", "summary": "\u2013 Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization \u2013 \u2013 ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile \u2013 \u2013 BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 \u2013 \u2013 PTC will host a conference call today, Aug. 12, at 5 p.m. ET \u2013 WARREN, N.J., Aug. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the", "url": "https://finance.yahoo.com/healthcare/articles/ptc-expand-rare-disease-portfolio-200100122.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T20:01:00+00:00", "published_display": "12 Aug 2026 20:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.309, "duplicate_count": 1, "topics": ["Acquisition", "Fda Approval", "Gene Therapy", "M A", "Rare Diseases", "Revenue Growth"]}, {"title": "Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026", "summary": "Earnings Call Insights: Taysha Gene Therapies (TSHA) Q2 2026 MANAGEMENT VIEW * \"The second quarter of 2026 was a highly productive period for Taysha,\" said CEO Sean Nolan, highlighting \"the completion of dosing in both the REVEAL pivotal and ASPIRE trials\" and progress \"toward a potential BLA submission for TSHA-102.\" (CEO & Chairman Sean Nolan) * Nolan said the REVEAL pivotal trial was \"over-enrolled\" with \"a total of 17 patients dosed with TSHA-102\" and described the age mix as \"reflective of the broader Rett syndrome population,\" which he said \"may support a broad label for TSHA-102.\" (CEO ", "url": "https://seekingalpha.com/news/4631192-taysha-outlines-reveal-6-month-interim-analysis-and-fda-feedback-in-h1-2027-while-targeting?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-12T01:38:39+00:00", "published_display": "12 Aug 2026 01:38", "sentiment": "neutral", "sentiment_pct": 53, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.22, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Fourth Quarter", "Regulation"]}, {"title": "Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Monday, Aug. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer - Thomas LeggettChief Executive Officer - Ian SmithChief Medical Officer - Barry TichoChief Patient Officer - Jason Hoitt Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Phase III Enrollment -- 162 patients, representing completion of the primary analysis population for the U.S., U.K., and Japan as of June 2026.EMPEROR Study Progress -- 145 patients through week 8 of treatment, including receipt of two 70 milligram loading doses of zorevunersen or a sham contr", "url": "https://www.nasdaq.com/articles/stoke-therapeutics-stok-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-11T01:58:36+00:00", "published_display": "11 Aug 2026 01:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.272, "duplicate_count": 1, "topics": ["Balance Sheet", "Clinical Trials", "Dravet Syndrome", "Fda Approval", "Financial Results", "Markets"]}, {"title": "ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights", "summary": "ProKidney Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experience Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- P", "url": "https://finance.yahoo.com/healthcare/articles/prokidney-reports-second-quarter-2026-200500887.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:05:00+00:00", "published_display": "10 Aug 2026 20:05", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.16, "duplicate_count": 1, "topics": ["Biotech", "Chronic Kidney Disease", "Clinical Trials", "Earnings", "Financial Results"]}, {"title": "Hormuz risk premium: Who wins and loses in the tanker trade", "summary": "[The tanker] Dikuch/iStock via Getty Images INVESTORS SHOULD KNOW: The Strait of Hormuz remains a live flashpoint for global oil markets, with Iran-Oman shipping talks nearing completion but full reopening still tied to unresolved U.S.-Iran demands. This keeps risk premiums embedded in tanker rates, pipeline economics, and crude logistics across the energy sector. BACKGROUND The Strait of Hormuz is the world's most critical oil chokepoint, with roughly one-fifth of global oil and LNG shipments transiting the waterway. Its partial or full closure has direct consequences for tanker rates, midstr", "url": "https://seekingalpha.com/news/4630121-hormuz-risk-premium-who-wins-and-loses-in-the-tanker-trade?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-10T18:25:59+00:00", "published_display": "10 Aug 2026 18:25", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.169, "duplicate_count": 1, "topics": ["Earnings", "Earnings Growth", "Energy", "Free Cash Flow", "Geopolitical Risk", "Midstream"]}, {"title": "Koppers Q2 Earnings Call Highlights", "summary": "Key Points Interested in Koppers Holdings Inc.? Here are five stocks we like better. Koppers lowered its 2026 adjusted EBITDA outlook to $240 million\u2013$250 million from ongoing cost pressures, particularly higher coal tar, freight and logistics costs in Carbon Materials and Chemicals. The company maintained its sales forecast of $1.9 billion\u2013$2 billion. Second-quarter sales increased 3% to $520 million, but adjusted EBITDA fell 7.9% to $71 million. Performance Chemicals delivered strong growth, while RUPS and Carbon Materials and Chemicals experienced profitability declines. Koppers generated r", "url": "https://finance.yahoo.com/markets/stocks/articles/koppers-q2-earnings-call-highlights-150358475.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T15:03:58+00:00", "published_display": "08 Aug 2026 15:03", "sentiment": "positive", "sentiment_pct": 57, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.238, "duplicate_count": 1, "topics": ["Cost Pressures", "Debt Reduction", "Dividends", "Earnings", "Earnings Per Share", "Free Cash Flow"]}, {"title": "Anika (ANIK) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stephen D. GriffinSenior Vice President, Chief Accounting Officer, and Treasurer - Ian W. McLeodExecutive Director, Corporate Development and Investor Relations - Matthew Hall TAKEAWAYS Total Revenue -- $32.6 million, an increase of 16% reflecting record performance in the commercial channel and strength in OEM sales.Commercial Channel Revenue -- $13.9 million, growing 17% year over year and representing the strongest quarterly performance in company history.In", "url": "https://www.nasdaq.com/articles/anika-anik-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-08T01:00:31+00:00", "published_display": "08 Aug 2026 01:00", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.18, "duplicate_count": 1, "topics": ["Balance Sheet", "Earnings", "Earnings Per Share", "Financial Results", "Fourth Quarter", "Free Cash Flow"]}], "by_tier": {"direct": [{"title": "Inovio (INO) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Director of Communications - Jennie WillsonPresident and Chief Executive Officer - Dr. Jacqueline E. SheaChief Medical Officer - Dr. Michael SumnerChief Commercial Officer - Steven EggeChief Financial Officer - Peter D. Kies TAKEAWAYS INO-3107 PDUFA Date -- Oct. 30, 2026, for the Inovio Pharmaceuticals, Inc.(NASDAQ:INO) Biologics License Application (BLA), representing the target action date for regulatory review.Cash and Cash Equivalents -- $36.7 million as of June 30, 2026, a decrease from $58.5 mi", "url": "https://www.nasdaq.com/articles/inovio-ino-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-13T00:58:58+00:00", "published_display": "13 Aug 2026 00:58", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.427, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Financial Results"]}, {"title": "PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program", "summary": "\u2013 Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization \u2013 \u2013 ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile \u2013 \u2013 BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 \u2013 \u2013 PTC will host a conference call today, Aug. 12, at 5 p.m. ET \u2013 WARREN, N.J., Aug. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the", "url": "https://finance.yahoo.com/healthcare/articles/ptc-expand-rare-disease-portfolio-200100122.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T20:01:00+00:00", "published_display": "12 Aug 2026 20:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.309, "duplicate_count": 1, "topics": ["Acquisition", "Fda Approval", "Gene Therapy", "M A", "Rare Diseases", "Revenue Growth"]}, {"title": "Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026", "summary": "Earnings Call Insights: Taysha Gene Therapies (TSHA) Q2 2026 MANAGEMENT VIEW * \"The second quarter of 2026 was a highly productive period for Taysha,\" said CEO Sean Nolan, highlighting \"the completion of dosing in both the REVEAL pivotal and ASPIRE trials\" and progress \"toward a potential BLA submission for TSHA-102.\" (CEO & Chairman Sean Nolan) * Nolan said the REVEAL pivotal trial was \"over-enrolled\" with \"a total of 17 patients dosed with TSHA-102\" and described the age mix as \"reflective of the broader Rett syndrome population,\" which he said \"may support a broad label for TSHA-102.\" (CEO ", "url": "https://seekingalpha.com/news/4631192-taysha-outlines-reveal-6-month-interim-analysis-and-fda-feedback-in-h1-2027-while-targeting?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-12T01:38:39+00:00", "published_display": "12 Aug 2026 01:38", "sentiment": "neutral", "sentiment_pct": 53, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.22, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Fourth Quarter", "Regulation"]}, {"title": "Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Monday, Aug. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer - Thomas LeggettChief Executive Officer - Ian SmithChief Medical Officer - Barry TichoChief Patient Officer - Jason Hoitt Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Phase III Enrollment -- 162 patients, representing completion of the primary analysis population for the U.S., U.K., and Japan as of June 2026.EMPEROR Study Progress -- 145 patients through week 8 of treatment, including receipt of two 70 milligram loading doses of zorevunersen or a sham contr", "url": "https://www.nasdaq.com/articles/stoke-therapeutics-stok-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-11T01:58:36+00:00", "published_display": "11 Aug 2026 01:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.272, "duplicate_count": 1, "topics": ["Balance Sheet", "Clinical Trials", "Dravet Syndrome", "Fda Approval", "Financial Results", "Markets"]}, {"title": "ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights", "summary": "ProKidney Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experience Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- P", "url": "https://finance.yahoo.com/healthcare/articles/prokidney-reports-second-quarter-2026-200500887.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:05:00+00:00", "published_display": "10 Aug 2026 20:05", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.16, "duplicate_count": 1, "topics": ["Biotech", "Chronic Kidney Disease", "Clinical Trials", "Earnings", "Financial Results"]}, {"title": "Hormuz risk premium: Who wins and loses in the tanker trade", "summary": "[The tanker] Dikuch/iStock via Getty Images INVESTORS SHOULD KNOW: The Strait of Hormuz remains a live flashpoint for global oil markets, with Iran-Oman shipping talks nearing completion but full reopening still tied to unresolved U.S.-Iran demands. This keeps risk premiums embedded in tanker rates, pipeline economics, and crude logistics across the energy sector. BACKGROUND The Strait of Hormuz is the world's most critical oil chokepoint, with roughly one-fifth of global oil and LNG shipments transiting the waterway. Its partial or full closure has direct consequences for tanker rates, midstr", "url": "https://seekingalpha.com/news/4630121-hormuz-risk-premium-who-wins-and-loses-in-the-tanker-trade?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-10T18:25:59+00:00", "published_display": "10 Aug 2026 18:25", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.169, "duplicate_count": 1, "topics": ["Earnings", "Earnings Growth", "Energy", "Free Cash Flow", "Geopolitical Risk", "Midstream"]}, {"title": "Koppers Q2 Earnings Call Highlights", "summary": "Key Points Interested in Koppers Holdings Inc.? Here are five stocks we like better. Koppers lowered its 2026 adjusted EBITDA outlook to $240 million\u2013$250 million from ongoing cost pressures, particularly higher coal tar, freight and logistics costs in Carbon Materials and Chemicals. The company maintained its sales forecast of $1.9 billion\u2013$2 billion. Second-quarter sales increased 3% to $520 million, but adjusted EBITDA fell 7.9% to $71 million. Performance Chemicals delivered strong growth, while RUPS and Carbon Materials and Chemicals experienced profitability declines. Koppers generated r", "url": "https://finance.yahoo.com/markets/stocks/articles/koppers-q2-earnings-call-highlights-150358475.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T15:03:58+00:00", "published_display": "08 Aug 2026 15:03", "sentiment": "positive", "sentiment_pct": 57, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.238, "duplicate_count": 1, "topics": ["Cost Pressures", "Debt Reduction", "Dividends", "Earnings", "Earnings Per Share", "Free Cash Flow"]}, {"title": "Anika (ANIK) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stephen D. GriffinSenior Vice President, Chief Accounting Officer, and Treasurer - Ian W. McLeodExecutive Director, Corporate Development and Investor Relations - Matthew Hall TAKEAWAYS Total Revenue -- $32.6 million, an increase of 16% reflecting record performance in the commercial channel and strength in OEM sales.Commercial Channel Revenue -- $13.9 million, growing 17% year over year and representing the strongest quarterly performance in company history.In", "url": "https://www.nasdaq.com/articles/anika-anik-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-08T01:00:31+00:00", "published_display": "08 Aug 2026 01:00", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.18, "duplicate_count": 1, "topics": ["Balance Sheet", "Earnings", "Earnings Per Share", "Financial Results", "Fourth Quarter", "Free Cash Flow"]}], "industry": [], "sector": []}, "total_fetched": 8, "total_unique": 8, "total_relevant": 8, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 8, "unique_stories": 8, "duplicates_removed": 0, "relevant_stories": 8, "current_evidence": 8, "direct_evidence": 8, "eodhd_articles": 8, "eodhd": {"configured": true, "status": "healthy", "calls_used": 170, "call_budget": 500, "budget_used_pct": 34.0, "requests_made": 34, "last_success_at": "2026-08-13T04:15:18.568399+00:00", "newest_seen_at": "2026-08-13T03:51:55+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3663, "unmapped_mentions": 1837}, "status": "healthy"}, "sentiment_summary": {"positive": 4, "negative": 2, "neutral": 2, "score": 53, "raw_score": 55, "total": 8, "evidence_count": 8, "effective_articles": 7.18, "direct_story_count": 8, "industry_story_count": 0, "sector_story_count": 0, "story_count": 8, "source_count": 3, "source_concentration": 0.3649, "direct_share": 100, "dispersion": 16, "confidence": 78, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-13T00:58:58+00:00", "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 81, "events": [{"event": "earnings", "label": "Earnings", "weight": 3.6, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 0.6, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.6, "count": 1}], "positive_events": 4, "negative_events": 2, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 8, "unique_stories": 8, "duplicates_removed": 0, "relevant_stories": 8, "current_evidence": 8, "direct_evidence": 8, "eodhd_articles": 8, "eodhd": {"configured": true, "status": "healthy", "calls_used": 170, "call_budget": 500, "budget_used_pct": 34.0, "requests_made": 34, "last_success_at": "2026-08-13T04:15:18.568399+00:00", "newest_seen_at": "2026-08-13T03:51:55+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3663, "unmapped_mentions": 1837}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 75.13, "latest_week": "2026-08-07", "one_week_move": 9.3, "four_week_move": 19.9, "twelve_week_move": 5.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.206148, "market_dynamics_buy_signal": false, "relative_strength": 0.985561, "fair_value_gap": 34.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.1317, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.3% over one week, +19.9% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "nasdaq.com", "count": 3}, {"label": "finance.yahoo.com", "count": 3}, {"label": "seekingalpha.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 8}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 6}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Evidence confidence", "value": "78/100", "tone": "positive", "text": "7.18 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "8", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "16/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+9.3% over one week, +19.9% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Inovio (INO) Q2 2026 Earnings Call Transcript"}], "updated_at": "2026-08-13T04:15:52.738566+00:00", "detail_intelligence": {"headline": "Price moving ahead of tone", "summary": "Balanced news tone is drawn from 8 fresh independent stories, including 8 company-specific items across 3 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 53, "display": "53", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Evidence confidence", "value": 78, "display": "78", "tone": "positive", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "8 direct stories"}, {"label": "Evidence agreement", "value": 84, "display": "84", "tone": "positive", "note": "16/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 90, "note": "7.18 effective stories"}, {"label": "Source breadth", "value": 60, "note": "3 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 76, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 84, "note": "cross-story consistency"}, {"label": "Source independence", "value": 64, "note": "lower publisher concentration"}], "freshness": 76, "source_independence": 64, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 2, "score": 70, "tone": "positive", "x": 729.0, "y": 98.6, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 2, "score": 42, "tone": "negative", "x": 820.6, "y": 149.6, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 1, "score": 70, "tone": "positive", "x": 866.4, "y": 98.6, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 2, "score": 56, "tone": "neutral", "x": 912.2, "y": 124.1, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 1, "score": 38, "tone": "negative", "x": 958.0, "y": 156.8, "volume_height": 26.0, "volume_y": 240.0}], "timeline_points": "729.0,98.6 820.6,149.6 866.4,98.6 912.2,124.1 958.0,156.8", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Deteriorating", "tone": "negative", "recent_score": 51, "prior_score": 70, "delta": -19, "recent_count": 6, "prior_count": 2, "volume_delta": 4}, "freshness_buckets": [{"label": "Last 24 hours", "count": 2, "share": 25}, {"label": "1 to 3 days", "count": 4, "share": 50}, {"label": "4 to 7 days", "count": 2, "share": 25}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "nasdaq.com", "count": 3, "share": 38, "score": 58, "tone": "positive"}, {"label": "finance.yahoo.com", "count": 3, "share": 38, "score": 57, "tone": "neutral"}, {"label": "seekingalpha.com", "count": 2, "share": 25, "score": 43, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 6, "share": 75, "score": 54, "tone": "neutral"}, {"label": "Deals and strategy", "count": 1, "share": 12, "score": 58, "tone": "positive"}, {"label": "Guidance", "count": 1, "share": 12, "score": 57, "tone": "neutral"}], "topics": [{"label": "Earnings", "count": 6, "share": 75}, {"label": "Financial Results", "count": 4, "share": 50}, {"label": "Fda Approval", "count": 4, "share": 50}, {"label": "Clinical Trials", "count": 4, "share": 50}, {"label": "Free Cash Flow", "count": 3, "share": 38}, {"label": "Biotech", "count": 3, "share": 38}, {"label": "Balance Sheet", "count": 3, "share": 38}, {"label": "Fourth Quarter", "count": 2, "share": 25}, {"label": "Earnings Per Share", "count": 2, "share": 25}, {"label": "Revenue Growth", "count": 1, "share": 12}], "supporting": [{"label": "Direct evidence", "text": "8 current stories are mapped specifically to CMC."}, {"label": "Source breadth", "text": "The read spans 3 publishers rather than depending on one outlet."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 84/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Price disagreement", "text": "Price is moving more forcefully than the current news tone suggests."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Inovio (INO) Q2 2026 Earnings Call Transcript", "summary": "Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Director of Communications - Jennie WillsonPresident and Chief Executive Officer - Dr. Jacqueline E. SheaChief Medical Officer - Dr. Michael SumnerChief Commercial Officer - Steven EggeChief Financial Officer - Peter D. Kies TAKEAWAYS INO-3107 PDUFA Date -- Oct. 30, 2026, for the Inovio Pharmaceuticals, Inc.(NASDAQ:INO) Biologics License Application (BLA), representing the target action date for regulatory review.Cash and Cash Equivalents -- $36.7 million as of June 30, 2026, a decrease from $58.5 mi", "url": "https://www.nasdaq.com/articles/inovio-ino-q2-2026-earnings-call-transcript", "source_name": "nasdaq.com", "published_at": "2026-08-13T00:58:58+00:00", "published_display": "13 Aug 2026 00:58", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.431, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Financial Results"]}, "article_count": 8, "updated_at": "2026-08-13T02:58:44.420523+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 55.8, "label": "13 Feb 2026", "close": 79.38, "index": 100.0}, {"x": 78.6, "y": 75.5, "label": "20 Feb 2026", "close": 76.55, "index": 96.4}, {"x": 115.3, "y": 99.9, "label": "27 Feb 2026", "close": 73.06, "index": 92.0}, {"x": 151.9, "y": 156.3, "label": "06 Mar 2026", "close": 64.97, "index": 81.8}, {"x": 188.6, "y": 184.9, "label": "13 Mar 2026", "close": 60.86, "index": 76.7}, {"x": 225.2, "y": 191.0, "label": "20 Mar 2026", "close": 59.98, "index": 75.6}, {"x": 261.8, "y": 204.2, "label": "27 Mar 2026", "close": 58.09, "index": 73.2}, {"x": 298.5, "y": 179.8, "label": "03 Apr 2026", "close": 61.59, "index": 77.6}, {"x": 335.1, "y": 150.5, "label": "10 Apr 2026", "close": 65.79, "index": 82.9}, {"x": 371.8, "y": 147.9, "label": "17 Apr 2026", "close": 66.17, "index": 83.4}, {"x": 408.4, "y": 126.9, "label": "24 Apr 2026", "close": 69.18, "index": 87.1}, {"x": 445.0, "y": 130.5, "label": "01 May 2026", "close": 68.66, "index": 86.5}, {"x": 481.7, "y": 114.5, "label": "08 May 2026", "close": 70.96, "index": 89.4}, {"x": 518.3, "y": 112.5, "label": "15 May 2026", "close": 71.25, "index": 89.8}, {"x": 555.0, "y": 107.9, "label": "22 May 2026", "close": 71.9, "index": 90.6}, {"x": 591.6, "y": 79.0, "label": "29 May 2026", "close": 76.05, "index": 95.8}, {"x": 628.2, "y": 93.9, "label": "05 Jun 2026", "close": 73.91, "index": 93.1}, {"x": 664.9, "y": 68.8, "label": "12 Jun 2026", "close": 77.51, "index": 97.6}, {"x": 701.5, "y": 106.3, "label": "19 Jun 2026", "close": 72.13, "index": 90.9}, {"x": 738.2, "y": 128.3, "label": "26 Jun 2026", "close": 68.98, "index": 86.9}, {"x": 774.8, "y": 180.2, "label": "03 Jul 2026", "close": 61.53, "index": 77.5}, {"x": 811.4, "y": 172.5, "label": "10 Jul 2026", "close": 62.64, "index": 78.9}, {"x": 848.1, "y": 146.2, "label": "17 Jul 2026", "close": 66.41, "index": 83.7}, {"x": 884.7, "y": 128.5, "label": "24 Jul 2026", "close": 68.95, "index": 86.9}, {"x": 921.4, "y": 130.1, "label": "31 Jul 2026", "close": 68.72, "index": 86.6}, {"x": 958.0, "y": 85.4, "label": "07 Aug 2026", "close": 75.13, "index": 94.6}], "sentiment_points": [{"x": 708.7, "y": 122.6, "label": "20 Jun 2026", "score": 54}, {"x": 712.0, "y": 124.5, "label": "20 Jun 2026", "score": 53}, {"x": 720.4, "y": 122.6, "label": "22 Jun 2026", "score": 54}, {"x": 721.9, "y": 124.5, "label": "22 Jun 2026", "score": 53}, {"x": 722.2, "y": 124.5, "label": "22 Jun 2026", "score": 53}, {"x": 722.5, "y": 124.5, "label": "23 Jun 2026", "score": 53}, {"x": 723.3, "y": 122.6, "label": "23 Jun 2026", "score": 54}, {"x": 733.2, "y": 124.5, "label": "25 Jun 2026", "score": 53}, {"x": 735.8, "y": 122.6, "label": "25 Jun 2026", "score": 54}, {"x": 739.9, "y": 119.0, "label": "26 Jun 2026", "score": 56}, {"x": 740.4, "y": 119.0, "label": "26 Jun 2026", "score": 56}, {"x": 744.1, "y": 117.1, "label": "27 Jun 2026", "score": 57}, {"x": 748.3, "y": 113.4, "label": "27 Jun 2026", "score": 59}, {"x": 749.2, "y": 111.6, "label": "28 Jun 2026", "score": 60}, {"x": 749.6, "y": 111.6, "label": "28 Jun 2026", "score": 60}, {"x": 754.2, "y": 111.6, "label": "29 Jun 2026", "score": 60}, {"x": 757.7, "y": 109.8, "label": "29 Jun 2026", "score": 61}, {"x": 765.5, "y": 111.6, "label": "01 Jul 2026", "score": 60}, {"x": 766.5, "y": 111.6, "label": "01 Jul 2026", "score": 60}, {"x": 775.8, "y": 109.8, "label": "03 Jul 2026", "score": 61}, {"x": 778.8, "y": 111.6, "label": "03 Jul 2026", "score": 60}, {"x": 779.7, "y": 109.8, "label": "03 Jul 2026", "score": 61}, {"x": 788.5, "y": 109.8, "label": "05 Jul 2026", "score": 61}, {"x": 794.8, "y": 106.1, "label": "06 Jul 2026", "score": 63}, {"x": 846.5, "y": 113.4, "label": "16 Jul 2026", "score": 59}, {"x": 859.5, "y": 117.1, "label": "19 Jul 2026", "score": 57}, {"x": 868.7, "y": 119.0, "label": "20 Jul 2026", "score": 56}, {"x": 869.2, "y": 119.0, "label": "21 Jul 2026", "score": 56}, {"x": 881.8, "y": 119.0, "label": "23 Jul 2026", "score": 56}, {"x": 882.5, "y": 119.0, "label": "23 Jul 2026", "score": 56}, {"x": 921.9, "y": 117.1, "label": "31 Jul 2026", "score": 57}, {"x": 928.7, "y": 117.1, "label": "01 Aug 2026", "score": 57}, {"x": 929.7, "y": 119.0, "label": "01 Aug 2026", "score": 56}, {"x": 932.1, "y": 119.0, "label": "02 Aug 2026", "score": 56}, {"x": 933.2, "y": 119.0, "label": "02 Aug 2026", "score": 56}, {"x": 933.8, "y": 119.0, "label": "02 Aug 2026", "score": 56}, {"x": 934.2, "y": 117.1, "label": "02 Aug 2026", "score": 57}, {"x": 934.8, "y": 117.1, "label": "02 Aug 2026", "score": 57}, {"x": 938.6, "y": 119.0, "label": "03 Aug 2026", "score": 56}], "price_path": "42.0,55.8 78.6,75.5 115.3,99.9 151.9,156.3 188.6,184.9 225.2,191.0 261.8,204.2 298.5,179.8 335.1,150.5 371.8,147.9 408.4,126.9 445.0,130.5 481.7,114.5 518.3,112.5 555.0,107.9 591.6,79.0 628.2,93.9 664.9,68.8 701.5,106.3 738.2,128.3 774.8,180.2 811.4,172.5 848.1,146.2 884.7,128.5 921.4,130.1 958.0,85.4", "sentiment_path": "708.7,122.6 712.0,124.5 720.4,122.6 721.9,124.5 722.2,124.5 722.5,124.5 723.3,122.6 733.2,124.5 735.8,122.6 739.9,119.0 740.4,119.0 744.1,117.1 748.3,113.4 749.2,111.6 749.6,111.6 754.2,111.6 757.7,109.8 765.5,111.6 766.5,111.6 775.8,109.8 778.8,111.6 779.7,109.8 788.5,109.8 794.8,106.1 846.5,113.4 859.5,117.1 868.7,119.0 869.2,119.0 881.8,119.0 882.5,119.0 921.9,117.1 928.7,117.1 929.7,119.0 932.1,119.0 933.2,119.0 933.8,119.0 934.2,117.1 934.8,117.1 938.6,119.0", "price_change": -5.4, "sentiment_change": 2, "latest_close": 75.13, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}